SEC EDGARJUL 61 min read$CLOV

Reynoso Jamie L. sold $33K of CLOV

Reynoso Jamie L. (CEO, Medicare Advantage) sold 6,229 shares of CLOVER HEALTH INVESTMENTS, CORP. /DE (CLOV) at $5.26 on 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Reynoso Jamie L.

Published Jul 6, 2026, 9:57 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Jul 6, 2026, 9:59 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$CLOV

Neutral

high confidence

Mentioned

$CLOV

Relevance

2/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$CLOVNeutralLow

Why it matters

The disclosed open-market sale by the CEO may slightly affect sentiment, but the presence of a pre-arranged 10b5-1 plan typically limits interpretability as a new fundamental signal.

Market read

Traders may monitor for patterns in insider activity, but this specific disclosure is unlikely to drive a major repricing without accompanying company-specific news.

What to watch

The filing does not state whether additional sales/buys occurred around the same period, nor does it provide context on total insider ownership changes beyond the post-transaction share count.

Relevance 2/10Novelty 3/10Timing: Filed same day (2026-07-06) after-hours/late session SEC Form 4 disclosure.

Background

The article is a primary-source SEC Form 4 insider transaction for Clover Health Investments Corp./DE.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CLOVNeutralHigh confidence

Context

Clover Health CEO Jamie L. Reynoso sold 6,229 shares on 2026-07-06 at $5.2600/share under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted and short-lived.

Evidence & confidence

This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory catalyst.

Market effects

Sector

Minimal; insider sale in a single healthcare payer/MA name does not materially change sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s explicitly a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than negative expectations.

Key entities

issuer
Clover Health Investments Corp./DE
Subject of the Form 4 insider transaction disclosure.
insider
Reynoso Jamie L.
CEO, Medicare Advantage; sold shares under a 10b5-1 plan.

Read at source ← All news

SEP 15

$ASTHMed

Astrana Health, Clover Health, Alignment Healthcare, and Novavax Stocks Trade Down, What You Need To Know

Several healthcare stocks fell after bipartisan lawmakers introduced the Protecting Approved Care Act, which aims to reform Medicare Advantage plans. The bill could increase medical loss ratios and administrative burdens for insurers. Astrana Health (ASTH) fell 2.7%, Clover Health (CLOV) 4.8%, Alignment Healthcare (ALHC) 12.6%, and Novavax (NVAX) 3.6%.

financialcontent.com2 min

SEP 11

$CLOVHigh

Clover Health (CLOV) Gets New ‘Buy’ Call, Higher PT, Climbs 8.5%

Clover Health (CLOV) shares rose 8.53% to $4.71 after Deutsche Bank initiated coverage with a 'buy' rating and $6 price target, citing growth potential in Medicare Advantage and its technology platform. The company reported Q2 net income of $28M, up from a $10.6M loss YoY, with revenues increasing 55.6% to $743.2M. Medicare Advantage membership grew 48% to 157,309. Clover raised its net income and revenue guidance for the year. Hedge fund holdings in CLOV increased fourfold to $79.06M.

yahoo.com2 min

SEP 10

$CLOVMed

Clover Health (CLOV) Shares Skyrocket, What You Need To Know

Clover Health (CLOV) shares rose 8.5% after Deutsche Bank initiated coverage with a Buy rating and $6.00 price target, citing growth in Medicare Advantage, its Clover Assistant platform, and its risk model. The stock has seen high volatility, with a 24.2% drop last year due to disappointing earnings and lowered guidance. CLOV is up 96.9% YTD but trades 12.3% below its 52-week high.

financialcontent.com2 min

SEP 10

$PGNYHighAI 8/10

Spotting Winners: Progyny (NASDAQ:PGNY) And Health Insurance Providers Stocks In Q2

Progyny (PGNY) and other health insurers reported Q2 earnings, with revenues beating estimates by 2.8% but guidance below expectations. PGNY's revenue grew 5.3% YoY, missing EBITDA guidance. CVS Health (CVS) reported 7.3% YoY revenue growth, beating estimates. Molina Healthcare (MOH) saw a 4.8% YoY revenue decline. Alignment Healthcare (ALHC) grew 31.6% YoY, while Clover Health (CLOV) saw 55.6% YoY growth. Stocks have declined since earnings, except CLOV, which rose 4.3%.

tradingview.com3 min

SEP 3

$CLOVHighAI 8/10

Clover Health (CLOV) Turns Profitable As Medicare Membership Explodes

Clover Health (CLOV) reported Q2 2026 net income of $28M, reversing a $10.6M loss from the prior year. Medicare Advantage membership grew 48% YoY to 157,309. Revenue rose 55.6% to $743.2M, and adjusted EBITDA more than doubled. The company raised its full-year guidance, including adjusted EBITDA to $70M-$85M and GAAP net income to $20M-$35M. Cash and investments increased 13.8% YoY to $443.0M.

insidermonkey.com3 min

AUG 20